Here’s some encouraging news about Fulcrum Therapeutics. The Cambridge, Massachusetts-based biotech that is developing a drug to treat Facioscapulohumeral muscular dystrophy has announced it has closed $80 million in series… Read More »
Fulcrum Therapeutics raises $80 million in series B
Gene editing takes big step forward in Duchenne dog model
Researchers at the University of Texas Southwestern Medical Center in Dallas announced that they have made a significant advance in demonstrating the possibility of using CRISPR gene editing technology as… Read More »
Facio broadens portfolio of potential drug development candidates
Reposted from Facio Therapies, Leiden, The Netherlands – August 30, 2018 Facio Therapies announced today that it has selected a second series of potential candidates for FSHD drug development. This… Read More »
An update on early-onset FSHD
A review of published studies to improve our understanding by Amanda Hill, Highlands Ranch, Colorado As many as 20 percent of patients with FSHD have an “infantile” or “early-onset” form, which… Read More »
The 2018 FSHD International Research Congress
The field has made astonishingly fast progress by Charis Himeda, PhD, University of Nevada, Reno Nearly 150 researchers, clinicians, patients, and industry partners convened at the FSH Society’s 2018 International Research… Read More »